Published in Sci Transl Med on November 30, 2011
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.50
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA (2015) 3.48
CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. Nat Neurosci (2013) 2.51
Biomarker modeling of Alzheimer's disease. Neuron (2013) 2.51
Brain β-amyloid load approaches a plateau. Neurology (2013) 2.50
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement (2014) 2.46
The A4 study: stopping AD before symptoms begin? Sci Transl Med (2014) 2.43
Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology (2012) 2.01
The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol (2014) 1.96
Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia (2012) 1.90
Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology (2013) 1.74
Using AD biomarker research results for clinical care: a survey of ADNI investigators. Neurology (2013) 1.63
Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study. Lancet Neurol (2015) 1.62
Sex modifies the APOE-related risk of developing Alzheimer disease. Ann Neurol (2014) 1.59
Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci U S A (2013) 1.46
Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimers Res Ther (2013) 1.44
Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease. Int Psychogeriatr (2012) 1.43
Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging (2012) 1.43
A novel approach to delayed-start analyses for demonstrating disease-modifying effects in Alzheimer's disease. PLoS One (2015) 1.41
Optimization of the All-D Peptide D3 for Aβ Oligomer Elimination. PLoS One (2016) 1.38
Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress. Annu Rev Med (2013) 1.36
The evolution of preclinical Alzheimer's disease: implications for prevention trials. Neuron (2014) 1.35
Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. Radiology (2012) 1.34
Preclinical Alzheimer disease-the challenges ahead. Nat Rev Neurol (2012) 1.25
Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease. Nat Rev Drug Discov (2013) 1.12
Development of positron emission tomography β-amyloid plaque imaging agents. Semin Nucl Med (2012) 1.09
Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective review. Alzheimers Res Ther (2013) 1.09
Rates of decline in Alzheimer disease decrease with age. PLoS One (2012) 1.07
CAP-advancing the evaluation of preclinical Alzheimer disease treatments. Nat Rev Neurol (2015) 1.05
Developing therapeutic antibodies for neurodegenerative disease. Neurotherapeutics (2013) 1.05
Circulating cell-free microRNA as biomarkers for screening, diagnosis and monitoring of neurodegenerative diseases and other neurologic pathologies. Front Cell Neurosci (2013) 1.04
Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography. Brain (2016) 0.99
Genetic susceptibility testing for neurodegenerative diseases: ethical and practice issues. Prog Neurobiol (2013) 0.98
Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimers Dement (2015) 0.98
Characterizing the preclinical stages of Alzheimer's disease and the prospect of presymptomatic intervention. J Alzheimers Dis (2013) 0.95
Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument. JAMA Neurol (2015) 0.95
Template based rotation: a method for functional connectivity analysis with a priori templates. Neuroimage (2014) 0.94
Enrichment and stratification for predementia Alzheimer disease clinical trials. PLoS One (2012) 0.93
Pharmacological lifespan extension of invertebrates. Ageing Res Rev (2012) 0.93
The pattern of atrophy in familial Alzheimer disease: volumetric MRI results from the DIAN study. Neurology (2013) 0.92
Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study. Aging (Albany NY) (2013) 0.92
Discovery of a novel pharmacological and structural class of gamma secretase modulators derived from the extract of Actaea racemosa. ACS Chem Neurosci (2012) 0.92
Regional fluorodeoxyglucose metabolism and instrumental activities of daily living across the Alzheimer's disease spectrum. J Alzheimers Dis (2014) 0.91
Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology. Neurology (2016) 0.90
Mild cognitive impairment: diagnosis, longitudinal course, and emerging treatments. Curr Psychiatry Rep (2014) 0.89
Elevation of brain magnesium prevents synaptic loss and reverses cognitive deficits in Alzheimer's disease mouse model. Mol Brain (2014) 0.88
Role of genes linked to sporadic Alzheimer's disease risk in the production of β-amyloid peptides. Proc Natl Acad Sci U S A (2012) 0.88
Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer's Disease? Trends Neurosci (2016) 0.87
Proton MRS in mild cognitive impairment. J Magn Reson Imaging (2013) 0.87
Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging (2015) 0.86
Should we disclose amyloid imaging results to cognitively normal individuals? Neurodegener Dis Manag (2013) 0.86
Familiarity-based memory as an early cognitive marker of preclinical and prodromal AD. Neuropsychologia (2013) 0.85
The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome. Front Behav Neurosci (2015) 0.84
Multiple γ-secretase product peptides are coordinately increased in concentration in the cerebrospinal fluid of a subpopulation of sporadic Alzheimer's disease subjects. Mol Neurodegener (2012) 0.84
A Peephole into the Brain: Neuropathological Features of Alzheimer's Disease Revealed by in vivo Two-Photon Imaging. Front Psychiatry (2012) 0.84
Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score. Alzheimers Dement (Amst) (2015) 0.83
Choosing Alzheimer's disease prevention clinical trial populations. Neurobiol Aging (2013) 0.81
Progress update: fluid and imaging biomarkers in Alzheimer's disease. Biol Psychiatry (2013) 0.81
Participation in cognitively-stimulating activities is associated with brain structure and cognitive function in preclinical Alzheimer's disease. Brain Imaging Behav (2015) 0.81
The neuritic plaque facilitates pathological conversion of tau in an Alzheimer's disease mouse model. Nat Commun (2016) 0.81
Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trials. Biomed Res Int (2014) 0.81
Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's disease. Neuropsychologia (2015) 0.81
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease. J Alzheimers Dis (2015) 0.80
Development of a psychometrically equivalent short form of the Face-Name Associative Memory Exam for use along the early Alzheimer's disease trajectory. Clin Neuropsychol (2014) 0.79
Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough. Imaging Med (2012) 0.79
SIST-M-IR activities of daily living items that best discriminate clinically normal elderly from those with mild cognitive impairment. Curr Alzheimer Res (2014) 0.79
Cognitive resilience in clinical and preclinical Alzheimer's disease: the Association of Amyloid and Tau Burden on cognitive performance. Brain Imaging Behav (2016) 0.79
Obstacles and opportunities in Alzheimer's clinical trial recruitment. Health Aff (Millwood) (2014) 0.79
Molecular imaging of Alzheimer disease pathology. AJNR Am J Neuroradiol (2014) 0.78
Alzheimer’s disease: the new promise. J Clin Invest (2012) 0.78
The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. J Prev Alzheimers Dis (2014) 0.78
Imaging Vascular Disease and Amyloid in the Aging Brain: Implications for Treatment. J Prev Alzheimers Dis (2015) 0.78
Our "energy-Ca(2+) signaling deficits" hypothesis and its explanatory potential for key features of Alzheimer's disease. Front Aging Neurosci (2014) 0.77
Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease. Croat Med J (2014) 0.77
Direct medical costs and source of cost differences across the spectrum of cognitive decline: a population-based study. Alzheimers Dement (2015) 0.77
Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials. Neurobiol Aging (2015) 0.77
Neuroinflammation impairs adaptive structural plasticity of dendritic spines in a preclinical model of Alzheimer's disease. Acta Neuropathol (2016) 0.77
Metal chaperones: a holistic approach to the treatment of Alzheimer's disease. Front Psychiatry (2012) 0.77
Uncoupling neuronal death and dysfunction in Drosophila models of neurodegenerative disease. Acta Neuropathol Commun (2016) 0.76
A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer's disease. Alzheimers Res Ther (2015) 0.76
Magnetic resonance spectroscopy in common dementias. Neuroimaging Clin N Am (2013) 0.76
Interictal spikes during sleep are an early defect in the Tg2576 mouse model of β-amyloid neuropathology. Sci Rep (2016) 0.76
The Apathy Evaluation Scale: A Comparison of Subject, Informant, and Clinician Report in Cognitively Normal Elderly and Mild Cognitive Impairment. J Alzheimers Dis (2015) 0.76
Predictive testing for Alzheimer's disease: suicidal ideation in healthy participants. Alzheimer Dis Assoc Disord (2015) 0.76
Structure-activity relationships for a series of compounds that inhibit aggregation of the Alzheimer's peptide, Aβ42. Chem Biol Drug Des (2014) 0.76
Discrepancies between fluid and crystallized ability in healthy adults: a behavioral marker of preclinical Alzheimer's disease. Neurobiol Aging (2016) 0.75
Recent Alzheimer's disease research highlights. Alzheimers Res Ther (2012) 0.75
Identifying the Alteration Patterns of Brain Functional Connectivity in Progressive Mild Cognitive Impairment Patients: A Longitudinal Whole-Brain Voxel-Wise Degree Analysis. Front Aging Neurosci (2016) 0.75
Disclosing genetic risk of Alzheimer's disease to cognitively impaired patients and visit companions: Findings from the REVEAL Study. Patient Educ Couns (2016) 0.75
White matter hyperintensities are more highly associated with preclinical Alzheimer's disease than imaging and cognitive markers of neurodegeneration. Alzheimers Dement (Amst) (2016) 0.75
Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies. Alzheimers Res Ther (2016) 0.75
Screening for mild cognitive impairment: If not now, when? CMAJ (2015) 0.75
Function and clinical meaningfulness of treatments for mild Alzheimer's disease. Alzheimers Dement (Amst) (2016) 0.75
Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward. Curr Alzheimer Res (2016) 0.75
Oral glucose tolerance testing to modulate plasma amyloid levels: A novel biomarker. Alzheimers Dement (Amst) (2015) 0.75
Are CSF Biomarkers Useful as Prognostic Indicators in Diagnostically Unresolved Cognitively Impaired Patients in a Normal Clinical Setting. Dement Geriatr Cogn Dis Extra (2016) 0.75
Cognitive/Clinical Endpoints for Pre-Dementia AD Trials. J Prev Alzheimers Dis (2016) 0.75
Presymptomatic cortical thinning in familial Alzheimer disease: A longitudinal MRI study. Neurology (2016) 0.75
Alzheimer's disease severity, objectively determined and measured. Alzheimers Dement (Amst) (2016) 0.75
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol (2007) 10.75
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol (2006) 9.99
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain (2009) 7.20
Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci (1996) 7.19
Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron (2009) 7.02
Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain (2008) 6.29
Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron (2004) 5.52
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging (2010) 5.49
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol (2010) 5.03
A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol (2009) 4.59
Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol (2009) 4.55
PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging (2007) 4.47
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain (2010) 4.39
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol (2011) 4.38
An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol (2012) 4.36
CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology (2007) 4.24
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol (2009) 3.65
Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol (2010) 3.64
Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology (2005) 3.58
Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology (2008) 3.54
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement (2011) 3.05
MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology (2009) 2.83
Resolving controversies on the path to Alzheimer's therapeutics. Nat Med (2011) 2.78
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol (2011) 2.75
Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol (2009) 2.66
Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol (2011) 2.57
Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther (2011) 2.51
Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol (2006) 2.25
Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1-42. Ann Neurol (2010) 2.15
Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch Neurol (2011) 1.83
Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord (2003) 1.67
Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging (2007) 1.61
Episodic memory decline predicts cortical amyloid status in community-dwelling older adults. J Alzheimers Dis (2011) 1.00
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol (2013) 9.43
Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement (2005) 7.90
Automatic classification of MR scans in Alzheimer's disease. Brain (2008) 6.71
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.67
A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement (2008) 6.39
Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol (2015) 5.10
Mild cognitive impairment: ten years later. Arch Neurol (2009) 5.02
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol (2004) 4.66
The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol (2010) 4.59
Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies. Neuroimage (2007) 4.41
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain (2010) 4.39
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25
A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med (2013) 4.11
Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain (2006) 4.07
Longitudinal stability of MRI for mapping brain change using tensor-based morphometry. Neuroimage (2006) 3.85
The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement (2010) 3.85
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA (2010) 3.58
3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. Brain (2007) 3.53
Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects. Neuroimage (2008) 3.40
Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort. Neuroimage (2010) 3.27
Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement (2010) 3.11
Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain (2012) 3.08
Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease. Neuroimage (2005) 3.06
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement (2011) 3.05
Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol (2012) 2.84
Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol (2011) 2.83
Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans. Alzheimers Dement (2010) 2.79
Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement (2010) 2.68
Magnetic resonance elastography of the brain. Neuroimage (2007) 2.59
Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. Brain (2007) 2.58
Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther (2011) 2.51
Longitudinal change of biomarkers in cognitive decline. Arch Neurol (2011) 2.51
Neuroimaging in Alzheimer disease: an evidence-based review. Neuroimaging Clin N Am (2003) 2.43
Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain (2012) 2.43
Automatic quality assessment in structural brain magnetic resonance imaging. Magn Reson Med (2009) 2.43
Effect of APOE ε4 status on intrinsic network connectivity in cognitively normal elderly subjects. Arch Neurol (2011) 2.40
3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry. Neuroimage (2008) 2.40
Association of ambulatory blood pressure with ischemic brain injury. Hypertension (2007) 2.39
Predicting clinical scores from magnetic resonance scans in Alzheimer's disease. Neuroimage (2010) 2.33
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2013) 2.32
Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer's disease mild cognitive impairment, and elderly controls. Neuroimage (2008) 2.30
Characterizing a neurodegenerative syndrome: primary progressive apraxia of speech. Brain (2012) 2.29
Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: an ADNI study of 515 subjects. Neuroimage (2009) 2.28
Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Hum Brain Mapp (2009) 2.28
Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging (2010) 2.27
Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol (2008) 2.25
Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Neuroimage (2008) 2.25
Methodological considerations for measuring rates of brain atrophy. J Magn Reson Imaging (2003) 2.16
Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol (2010) 2.16
Boosting power for clinical trials using classifiers based on multiple biomarkers. Neurobiol Aging (2010) 2.13
A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly. Proc Natl Acad Sci U S A (2010) 2.12
Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. Lancet Neurol (2012) 2.09
Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort. Neurobiol Aging (2010) 2.05
Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. Neuroimage (2009) 2.03
Brain injury biomarkers are not dependent on β-amyloid in normal elderly. Ann Neurol (2013) 2.03
Patterns of atrophy in pathologically confirmed FTLD with and without motor neuron degeneration. Neurology (2006) 2.01
Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology (2012) 2.01
Prominent phenotypic variability associated with mutations in Progranulin. Neurobiol Aging (2007) 2.00
Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. Neuroimage (2008) 1.98
Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T. AJNR Am J Neuroradiol (2003) 1.96
Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch Neurol (2010) 1.94
Genome-wide analysis reveals novel genes influencing temporal lobe structure with relevance to neurodegeneration in Alzheimer's disease. Neuroimage (2010) 1.94
Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study. Brain (2009) 1.93
Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol (2008) 1.93
Intensity non-uniformity correction using N3 on 3-T scanners with multichannel phased array coils. Neuroimage (2007) 1.93
Voxel-based morphometry in autopsy proven PSP and CBD. Neurobiol Aging (2006) 1.92
Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. Arch Neurol (2005) 1.91
Rates of cerebral atrophy differ in different degenerative pathologies. Brain (2007) 1.90
Non-stationarity in the "resting brain's" modular architecture. PLoS One (2012) 1.90
The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav (2014) 1.90
Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond) (2012) 1.90
Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med (2009) 1.90
Measurement of MRI scanner performance with the ADNI phantom. Med Phys (2009) 1.85
Patterns of atrophy differ among specific subtypes of mild cognitive impairment. Arch Neurol (2007) 1.84
Spherical navigator echoes for full 3D rigid body motion measurement in MRI. Magn Reson Med (2002) 1.83
Interpreting scan data acquired from multiple scanners: a study with Alzheimer's disease. Neuroimage (2007) 1.83
Common variants at 12q14 and 12q24 are associated with hippocampal volume. Nat Genet (2012) 1.79
Ecology of the aging human brain. Arch Neurol (2011) 1.78
Imaging markers for Alzheimer disease: which vs how. Neurology (2013) 1.76
Unbiased tensor-based morphometry: improved robustness and sample size estimates for Alzheimer's disease clinical trials. Neuroimage (2012) 1.76
Decreased brain stiffness in Alzheimer's disease determined by magnetic resonance elastography. J Magn Reson Imaging (2011) 1.72
Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: tissue-specific intensity normalization and parameter selection. Neuroimage (2009) 1.71
Blood pressure and white-matter disease progression in a biethnic cohort: Atherosclerosis Risk in Communities (ARIC) study. Stroke (2009) 1.70
3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging (2010) 1.70